ACE2 and COVID-19: Ace2 co-varies with many genes that are enriched in pathways related to inflammation and cardiac damage, suggesting that all these novel genes (Cyld, Jun, Mapk8, and Mapk14) and pathways (RAS, TGFβ, TNFα, and p38α) can be targeted for preventive, diagnostic, and therapeutic purposes in patients with cardiac damage, including COVID-19 patients.